Wellinks, a company specializing in digital solutions for chronic obstructive pulmonary disease (COPD), has appointed Stacie Bratcher as its new CEO. Bratcher has previously served as CEO of Jet Health and Alana Healthcare, as well as holding the position of board chair at GripAble. In her new role, Bratcher aims to leverage virtual solutions to improve outcomes for patients with complex chronic conditions.
Wellinks offers a digital platform and connected devices to track COPD treatments, symptoms, and vitals. Their platform also provides coaching and pulmonary rehab services. In addition to software solutions, Wellinks offers connected devices such as nebulizers and pulse oximeters.
COPD affects a significant portion of the American population, with one in eight Americans aged 45 and older impacted by the condition. Over 16 million Americans have been diagnosed with COPD, highlighting the need for effective management and treatment options.
Wellinks, previously known as Convexity Scientific, recently secured $25 million in Series C funding. This funding will enable the company to further develop and expand its offerings in the COPD space. In line with their growth plans, Wellinks recently partnered with Highmark Blue Cross Blue Shield of Delaware to provide COPD care to underserved populations in the state.
In the realm of digital health, other companies are also tackling COPD. Respiree, a med tech spinoff of Singapore’s Agency for Science, Technology and Research, has obtained FDA 510(k) clearance for its wearable cardio-respiratory sensor device. This device directly measures respiration in patients with cardio-pulmonary diseases like COPD and congestive heart failure.
Bratcher’s appointment as CEO comes at an opportune time, as there is a growing focus on innovations in healthcare and managing complex chronic conditions. With a strong background in the healthcare industry and experience leading companies focused on chronic care management, Bratcher is well-positioned to drive Wellinks’ growth and improve outcomes for COPD patients.
In a statement to MobiHealthNews, Bratcher expressed her enthusiasm for this opportunity, emphasizing the potential of virtual solutions to make a significant impact on patient outcomes. With the rising demand for virtual healthcare solutions and the increasing prevalence of COPD, Wellinks is well-positioned to make a positive impact in the field.
